LIS Technologies Inc S-1/Aamended IPO prospectus
NegativeBankruptcy / going concernPre-revenue
Developing lab-validated CRISLA laser uranium enrichment, with commercial operations targeted around 2033
Filed 2026-11-17 17:44 ET · Plans to list on Nasdaq
How this filing reads
Each score is our read of the filing's tone, not a rating. The bar runs from −1 (bad) to +1 (good). The tick marks the typical filing on Goblin, and the shaded band is where the middle half of filings score.How we read filings
- HealthCash of $18.8M trails $74M planned needs through July 2027; nine-month FCF outflow was $39.7M.
- MomentumNo revenue; the development-stage business has not enough history to assess momentum.
- OutlookThe $1.38B facility goal and $74M near-term cash needs lack committed funding.
A registration statement filed before the IPO. The offering price, if shown, is a proposed range; later amendments or the final prospectus may change the terms.
Changes since the S-1/A filed 2026-11-05
LIS disclosed export-control violations involving sensitive information, with remediation taken but no response yet from NNSA.
The filing adds export-compliance and management disclosures and raises offering costs, while leaving the final IPO price unset; it adds no financial period.
All 3 changes
- New Export-control violations
LIS self-reported Part 810 information-handling violations in September 2026; remediation was taken, but NNSA has not responded. LIS considers operational impact immaterial; penalties or export restrictions remain possible. - Changed Offering costs
Underwriter allowance 0.5%; estimated net proceeds $16.6 million, or $19.2 million with over-allotment. → The underwriter allowance rises to 1.15% and other offering expenses increase, reducing estimated net proceeds to $16.4 million, or $19.0 million with full over-allotment. - New Yu’s outside commitments
Jay Jiang Yu also founded longevity-and-wellness developer Human Continuum and remains its Executive Chairman and President, expecting to spend about two hours weekly there after the IPO.
Executive Summary
LIS Technologies is developing laser-enriched uranium for utilities and advanced-reactor companies, intending to earn revenue from fuel sales but selling none today. Its CRISLA process remains laboratory-validated; management targets commercial operations around 2033 and expects years without meaningful revenue. The latest nine-month net loss was $(29.7)M, while the all-primary IPO would raise $15.5M–$21.7M gross. Buyers would acquire 2.89% on a fully diluted basis at an implied fully diluted valuation of $536M–$750M, accepting that technical validation, licensing, customers and substantially more financing must follow.
Business Model and Growth Drivers
The opportunity is domestic enrichment supply: restrictions on Russian imports and potential reactor growth could increase demand. LIS has no fuel-purchase agreements, however, and established competitors such as Urenco and Centrus have operating infrastructure and customer relationships.
CRISLA uses continuous-wave carbon-monoxide lasers to selectively excite uranium isotopes in uranium hexafluoride gas. LIS reports a historical separation factor of 6.7 vs ≈1.25 for centrifuges, potentially reducing enrichment stages—but this is not demonstrated industrial performance. A 03/2025 independent assessment found laboratory validation, not validation in an industrially relevant environment. Laboratory optimization is planned through 2027 and industrial-equipment development through 2028. Management targets pilot readiness around 2030 before commercial production; reliability, purity, throughput and economics remain unproven.
LIS owns the 206-acre LIST Island site in Oak Ridge. Its announced commercial-facility investment goal is $1.38B, far beyond this IPO. Claimed cost advantages are projections, and the prospectus’s operating-cost calculations are internally inconsistent. Former CRISLA shareholders also receive royalties of 5% of annual net sales.
Government participation is not construction funding. LIS belongs to a Department of Energy multiple-award program, but receives payment only for awarded work. Potential state and local incentives exceeding $200M are conditional and unreceived. NANO Nuclear’s proposed feedstock-and-fuel collaboration lacks definitive commercial terms and can be terminated on 90 days’ notice.
The Offering
- Unpriced: 3.10M primary shares at $5.00–$7.00, with no secondary sales. Implied gross proceeds are $15.5M–$21.7M; 74.8114M post-offering shares imply capitalization of $374M–$524M and a 4.14% buyer stake. Fully diluted shares total 107.183M, implying $536M–$750M and 2.89%. This adds outstanding options, restricted stock units, representative warrants and 3.20M contingent acquisition shares; it excludes ungranted reserves and counts issued Starfire shares once. Revenue and earnings multiples are not meaningful.
- Titan Partners Securities leads the deal; Nasdaq approval under “LIS” is required. The 30-day option covers 0.465M additional shares. At the $6.00 midpoint, estimated net proceeds are $16.4M, or $19.0M with full exercise.
- All proceeds go to LIS: 67.5% for technology and facility development, 12.5% for marketing and business development, and 20% for working capital and corporate purposes. Management may reallocate spending.
- Titan receives a 6.5% discount, 1.15% allowance and warrants covering 7% of shares sold, exercisable at 115% of the IPO price. A Titan affiliate previously invested $1.00M; this is not lender repayment.
- Dilution: each midpoint-priced share is backed by $0.68 of net tangible assets after the IPO, a $5.32 gap. Existing holders paid $1.05 per share on average.
- CEO Jay Jiang Yu and President Christo Liebenberg each indicated nonbinding purchases up to $0.250M. Insider purchases reduce public availability. Executives, directors and affiliates face 180-day lock-ups; certain other large holders have staged releases after 90, 120 and 180 days, creating future selling supply.
Key Financial Highlights
Fiscal years end 10/31; nine-month periods end 07/31. Amounts below are $M. “After IPO” assumes subsequent option exercises and the midpoint base offering, without over-allotment.
| Metric | FY2024 | FY2025 | 9M FY2025 | 9M FY2026 | After IPO | Investor interpretation |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | Development, not customer sales, determines results. |
| R&D | 1.42 | 3.87 | 2.58 | 11.4 | — | Work shifted heavily toward CRISLA. |
| Operating loss | (11.6) | (15.8) | (12.1) | (27.2) | — | Technical work and staffing expanded. |
| Net loss | (13.7) | (21.5) | (18.2) | (29.7) | — | Noncash acquisition revaluation adds volatility. |
| Operating cash flow | (3.20) | (8.35) | (5.42) | (14.8) | — | Equity compensation reduces cash expense relative to loss. |
| FCF: operating cash flow minus capital spending | (3.40) | (10.2) | (6.50) | (39.7) | — | Property and project investment dominate funding needs. |
| Cash | 16.6 | 33.2 | — | 18.8 | 37.8 | New financing replenishes depleted liquidity. |
| Stockholders’ equity | 15.6 | 26.2 | — | 32.4 | 51.3 | Share issuance offsets accumulated losses. |
| Tangible equity | 14.3 | 24.9 | — | 30.7 | 49.7 | Excludes acquired technology assets. |
- Spending drivers: nine-month CRISLA laboratory expense reached $10.1M from $0.619M; additional payroll and consulting contributed ≈$5M to administrative-cost growth.
- Loss vs cash: stock-based compensation was $10.5M; acquisition revaluation added $3.20M without immediate cash payment because the promised shares became more valuable. Capital purchases included ≈$8M for LIST Island, $6.1M for another property and ≈$9M for project development.
- Capitalization bridge: subsequent option exercises add $2.57M to cash and equity; the assumed IPO adds another $16.4M. Total liabilities remain $18.6M.
Governance and Control
- Common shares carry one vote each. Yu’s reported post-IPO beneficial ownership is 25%; directors and executives together hold 30.1%, including exercisable options. These are not pure outstanding-vote percentages.
- Yu chairs both LIS and related-party NANO Nuclear, which invested in LIS and supplies leased premises. Commercial negotiations therefore involve overlapping interests.
- Outstanding options and restricted stock units cover 29.0M shares, or 27.0% of fully diluted shares. The units alone are worth $30.7M at the midpoint before vesting restrictions; recognized compensation uses grant-date values rather than current market value.
Risk Assessment
- Liquidity and controls: planned cash requirements are ≈$74M through 07/31/2027; management alleviated going-concern doubt by assuming discretionary deferrals, while public-company controls remain underdeveloped.
- Technical scale-up: laboratory success may not survive industrial throughput, contamination, alignment and durability demands.
- Licensing and export controls: commercial licenses remain outstanding, and LIS self-disclosed document-handling violations in 09/2026; restrictions or remediation could delay development.
- Key-person dependence: Yu’s substantial outside commitments and scarce technical expertise create execution exposure if leadership becomes unavailable.
- Commercial and valuation exposure: the valuation precedes proven economics or customers; mature competitors could secure demand first, while further financing dilutes buyers.
- Uninsured hazards: LIS lacks specialized nuclear and pollution liability coverage, leaving potentially severe incident costs exposed.
What to Watch
- CRISLA testing: uranium experiments were expected by year-end 2026; reproducible enrichment and industrial-equipment results would support scale-up, while redesigns would undermine timing.
- Licensing: management plans an application in Q1 2027; acceptance and review progress would support the schedule, while deficiencies would challenge it.
- Customers and funding: binding fuel contracts and committed capital would validate commercialization; continued frameworks and spending deferrals would leave it unfinanced.
Longer version: the summary of each of the prospectus's 25 sections, written by an AI model from the same filing.
Get emails when companies you follow file: email digest settings.
The summary and scores is written by an AI model reading the filing.
Model 006 · prompt v230 · 2026-11-18 15:42:53Z